200 related articles for article (PubMed ID: 25963568)
21. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
22. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
23. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
Zhou SF
Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
[TBL] [Abstract][Full Text] [Related]
24. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
Mudra DR; Desino KE; Desai PV
Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
26. Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine.
Akazawa T; Yoshida S; Ohnishi S; Kanazu T; Kawai M; Takahashi K
Drug Metab Dispos; 2018 Nov; 46(11):1497-1506. PubMed ID: 30135242
[TBL] [Abstract][Full Text] [Related]
27. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q
PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360
[TBL] [Abstract][Full Text] [Related]
28. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
29. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
Adachi Y; Suzuki H; Sugiyama Y
Pharm Res; 2001 Dec; 18(12):1660-8. PubMed ID: 11785684
[TBL] [Abstract][Full Text] [Related]
30. Development of an in silico model for predicting efflux substrates in Caco-2 cells.
Zhang L; Balimane PV; Johnson SR; Chong S
Int J Pharm; 2007 Oct; 343(1-2):98-105. PubMed ID: 17583455
[TBL] [Abstract][Full Text] [Related]
31. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2021 May; 17(5):555-580. PubMed ID: 33703995
[No Abstract] [Full Text] [Related]
32. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
[TBL] [Abstract][Full Text] [Related]
33. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of drug efflux pumps in the gut.
Misaka S; Müller F; Fromm MF
Curr Opin Pharmacol; 2013 Dec; 13(6):847-52. PubMed ID: 24028838
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination.
Chen EC; Broccatelli F; Plise E; Chen B; Liu L; Cheong J; Zhang S; Jorski J; Gaffney K; Umemoto KK; Salphati L
Mol Pharm; 2018 Nov; 15(11):5103-5113. PubMed ID: 30222362
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
Kim WY; Benet LZ
Pharm Res; 2004 Jul; 21(7):1284-93. PubMed ID: 15290871
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.
Hochman JH; Yamazaki M; Ohe T; Lin JH
Curr Drug Metab; 2002 Jun; 3(3):257-73. PubMed ID: 12083320
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
39. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
40. Suitability of RPMI 2650 cell models for nasal drug permeability prediction.
Sibinovska N; Žakelj S; Kristan K
Eur J Pharm Biopharm; 2019 Dec; 145():85-95. PubMed ID: 31639418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
